INSILICO (03696) has announced its inclusion in several China Securities Index series. The company will be added to the CSI Hong Kong Stock Connect Innovative Drug Index (Code: 931250), the CSI Hong Kong Innovative Drug Index (Code: 931787), and the CSI Hong Kong Stock Connect Healthcare Composite Index (Code: 930965).

This inclusion is scheduled to take effect from Monday, June 15, 2026. Since its listing on The Stock Exchange of Hong Kong Limited, INSILICO has been progressively added to several other major index series prior to this recognition from the China Securities Index series. These include the Hang Seng Composite Index, the Hang Seng Healthcare Index, the Hang Seng Biotechnology Index, the FTSE Global Small Cap Index, the FTSE Global All Cap Index, and the FTSE Global Total Cap Index.

The company's board of directors believes that its addition to these index series reflects market recognition of its solid fundamentals, technological capabilities, and growth potential. This inclusion is expected to enhance the company's visibility among international institutional investors and research analysts, attract passive fund inflows that track the relevant indices, diversify its shareholder base, and improve the trading liquidity of its shares.